PHAT

Phathom Pharmaceuticals Inc

5.74

Oct 30 • 3:59 PM ET -0.48 (-7.72%)

5.85

Aftermarket • 7:30 PM ET +0.11 (1.92%)

Healthcare Biotechnology USA Small NASD

Oct 30, 5:31 PMNo clear catalyst identified for after-hours rebound after day's drop

Peers: ARDX IRWD RIGL TAK BHC HRMY COLL EOLS AQST SUPN

| Held by: VTI IWM VXF XPH IBB VTWO IWN SCHA SURI IHE

Scroll to Statements

Index	RUT
Market Cap	466.61M
Enterprise Value	837.50M
Income	-83.00M
Sales	274.88M
Book/sh	-4.28
Cash/sh	2.27
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	371
IPO	Oct 25, 2019

P/E	-
Forward P/E	8.73
PEG	-
P/S	1.70
P/B	-
P/C	2.53
P/FCF	-
EV/EBITDA	-
EV/Sales	3.05
Quick Ratio	1.72
Current Ratio	1.76
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-1.03
EPS next Y	0.66
EPS next Q	-0.07
EPS this Y	75.58%
EPS next Y	188.89%
EPS next 5Y	-
EPS past 3/5Y	15.64% 4.82%
Sales past 3/5Y	- -
EPS Y/Y TTM	72.98%
Sales Y/Y TTM	86.75%
EPS Q/Q	59.92%
Sales Q/Q	71.14%
Earnings	Oct 29 BMO
EPS/Sales Surpr.	-45.85% -0.12%

Insider Own	36.68%
Insider Trans	0.00%
Inst Own	60.12%
Inst Trans	7.29%
ROA	-28.36%
ROE	-
ROIC	-49.81%
Gross Margin	80.68%
Oper. Margin	-9.26%
Profit Margin	-30.19%
SMA20	-14.89%
SMA50	-24.88%
SMA200	-45.03%
Trades

Shs Outstand	81.22M
Shs Float	51.23M
Short Float	19.10%
Short Ratio	6.29
Short Interest	9.78M
52W High	18.31 -68.65%
52W Low	5.01 14.46%
Volatility	11.65% 8.59%
ATR (14)	0.58
RSI (14)	33.51
Beta	0.66
Rel Volume	1.04
Avg Volume	1.56M
Volume	1,620,389

Perf Week	0.00%
Perf Month	-18.93%
Perf Quarter	-36.08%
Perf Half Y	-52.21%
Perf YTD	-65.40%
Perf Year	-56.87%
Perf 3Y	-36.08%
Perf 5Y	-75.61%
Perf 10Y	-
Recom	1.30
Target Price	20.05
Prev Close	6.22
Price	5.74
Change %	-7.72%

Consensus

Strong Buy

Avg. Price Target

$20.05

Implied Upside

+249.3%

Analysts13incl. previous ratings

Rating Distribution11 Buy · 2 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 09, 2026	Initiated	LLeerink Partners	Market Perform	$10	+74.2%
Mar 27, 2026	Upgrade	BBarclays	Equal Weight → Overweight	$18	+213.6%
Dec 12, 2025	Initiated	RRaymond James	Strong Buy	$28	+387.8%
Dec 09, 2025	Initiated	BBarclays	Equal Weight	$16	+178.7%
Feb 14, 2025	Initiated	CCantor Fitzgerald	Overweight	$23	+300.7%
May 03, 2024	Initiated	SStifel	Buy	$24	+318.1%
Jan 05, 2024	Reiterated	NNeedham	Buy	$23 → $26	+353.0%
Aug 09, 2023	Initiated	HH.C. Wainwright	Buy	$28	+387.8%
May 11, 2023	Upgrade	EEvercore ISI	In-line → Outperform
Mar 13, 2023	Initiated	CCraig Hallum	Buy	$21	+265.9%
Oct 21, 2022	Initiated	JJefferies	Buy	$16	+178.7%
May 06, 2022	Downgrade	EEvercore ISI	Outperform → In-line
May 12, 2021	Upgrade	GGoldman	Sell → Neutral	$40 → $48	+736.2%
Feb 17, 2021	Initiated	BBMO Capital Markets	Outperform	$63	+997.6%
Feb 02, 2021	Initiated	GGuggenheim	Buy	$60	+945.3%
Jun 26, 2020	Downgrade	GGoldman	Neutral → Sell	$34	+492.3%
Nov 20, 2019	Initiated	EEvercore ISI	Outperform
Nov 19, 2019	Initiated	NNeedham	Buy	$40	+596.9%
Nov 19, 2019	Initiated	JJefferies	Buy	$32	+457.5%
Nov 19, 2019	Initiated	GGoldman	Neutral	$32	+457.5%

Oct-29-26 11:08AM	Phathom Misses On A Decelerating Quarter As Cash-Flow Progress Collides With A New VOQUEZNA Exclusivity Overhang (Earnings Whispers)
07:00AM	Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
Oct-26-26 04:00AM	Phathom Pharmaceuticals Provides Update on FDA Litigation (GlobeNewswire)
Oct-23-26 01:45PM	PHAT Stock Eyes Worst Day In Nearly Two Years After Generic Drug Maker Challenges Key Drugs Exclusivity (Stocktwits) -18.12%
04:00AM	Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA (GlobeNewswire)
01:38PM	Loading…
Oct-21-26 01:38PM	Phathom's Prescribing Friction Faces Its First Test After Guidance Cut Rattled Investors (Earnings Whispers)
Oct-19-26 08:00AM	Phathom Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide Business Update on Thursday, October 29, 2026 (GlobeNewswire)
Oct-12-26 08:00AM	Phathom Pharmaceuticals Highlights New Cost-Effectiveness Data and Growing Clinical Interest in VOQUEZNA (vonoprazan) at ACG 2026 (GlobeNewswire)
Oct-08-26 08:00AM	Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting (GlobeNewswire)
Sep-29-26 08:00AM	Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA (vonoprazan) for As-Needed Treatment of Non-Erosive GERD (GlobeNewswire)
Sep-09-26 01:26PM	PHAT Stock Falls 7% As Leerink Sees Little Near-Term Upside CEO Plays Down Upcoming Rival (Stocktwits) -8.06%
Sep-01-26 08:00AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jul-30-26 06:09PM	PHAT Stock Clocks Worst Day In Over 1.5 Years What Sparked The Selloff? (Stocktwits) -22.42%
03:01PM	Phathom Pharmaceuticals Inc (PHAT) (Q2 2026) Earnings Call Highlights: First Positive Operating ... (GuruFocus.com)
06:59AM	Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
09:58AM	Loading…
Jul-29-26 09:58AM	Earnings To Watch: Phathom Pharmaceuticals Inc (PHAT) Reports Q2 2026 Result (GuruFocus.com)
Jul-20-26 08:00AM	Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026 (GlobeNewswire)
Jun-23-26 07:59AM	Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA (vonoprazan) in Eosinophilic Esophagitis (EoE) (GlobeNewswire)
May-22-26 08:00AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-20-26 08:00AM	Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting (GlobeNewswire)
May-01-26 08:00AM	Phathom Pharmaceuticals to Highlight VOQUEZNA (vonoprazan) at DDW 2026 Annual Meeting (GlobeNewswire) +7.23%
Apr-30-26 06:59AM	Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
Apr-29-26 09:24AM	Phathom Pharmaceuticals Inc (PHAT) Q1 2026: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Apr-20-26 08:00AM	Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026 (GlobeNewswire)
Apr-06-26 08:00AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-01-26 04:27AM	Guggenheim Raises PT on Phathom Pharmaceuticals (PHAT) to $25 From $20, Here's Why (Insider Monkey)
Feb-27-26 04:30AM	Phathom Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat) -7.37%
Feb-26-26 04:12PM	Phathom Pharmaceuticals Inc (PHAT) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com) +10.06%
12:15PM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
07:00AM	Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance (GlobeNewswire)
07:33AM	Loading…
Feb-25-26 07:33AM	What To Expect From Phathom Pharmaceuticals Inc (PHAT) Q4 2025 Earnings (GuruFocus.com) +6.12%
Feb-24-26 09:40AM	Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Feb-23-26 08:00AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-17-26 08:00AM	Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026 (GlobeNewswire) +6.16%
Feb-14-26 05:05PM	Phathom Pharmaceuticals Pivots to GI Focus, Targets 2H 2026 Profitability, CEO Says at Guggenheim Summit (MarketBeat)
Feb-05-26 08:00AM	Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026 (GlobeNewswire) -6.20%
Jan-08-26 08:49AM	Phathom's Early Numbers Show Sales Strength, Eyes 2026 Profitability (Benzinga) -13.72%
05:17AM	Stock Market Today: S&P 500, Dow Jones Futures Decline - AZZ, Northrop Grumman, Immuneering In Focus (Benzinga)
Jan-07-26 10:33PM	Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +10.45%
04:05PM	Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
04:01PM	Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Dec-25-25 07:00PM	Raymond James Sees an Attractive Setup in These 2 Strong Buy Stocks (TipRanks)
Nov-04-25 08:00AM	Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA (vonoprazan) in Eosinophilic Esophagitis (EoE) (GlobeNewswire)
Nov-03-25 07:59AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-30-25 04:24PM	Phathom Pharmaceuticals Inc (PHAT) Q3 2025 Earnings Call Highlights: Revenue Surge and ... (GuruFocus.com)
08:15AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Oct-29-25 09:49AM	Phathom Pharmaceuticals Inc (PHAT) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-25-25 09:59AM	Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease (GlobeNewswire)
Oct-23-25 08:00AM	Phathom Pharmaceuticals to Highlight VOQUEZNA (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting (GlobeNewswire)
Oct-20-25 08:00AM	Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025 (GlobeNewswire) +8.10%
Oct-06-25 08:00AM	Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer (GlobeNewswire)
Sep-18-25 12:00PM	Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's Why (Zacks) +6.82%
Sep-08-25 05:04PM	Wall Street Analysts See a 66.13% Upside in Phathom Pharmaceuticals (PHAT): Can the Stock Really Move This High? (Zacks)
Aug-25-25 07:59AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-22-25 09:55AM	Wall Street Analysts Think Phathom Pharmaceuticals (PHAT) Could Surge 87.21%: Read This Before Placing a Bet (Zacks) +8.77%
Aug-20-25 08:00AM	Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder's Ownership Following Administrative Change to 13D Filing (GlobeNewswire)
Aug-07-25 08:10AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +8.29%
06:59AM	Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-06-25 08:25AM	MannKind (MNKD) Reports Break-Even Earnings for Q2 (Zacks)
Aug-04-25 08:15AM	Krystal Biotech, Inc. (KRYS) Tops Q2 Earnings and Revenue Estimates (Zacks)
Jul-28-25 08:00AM	Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025 (GlobeNewswire) -8.62%
Jun-23-25 04:15PM	Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -9.12%
07:59AM	Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary (GlobeNewswire)
Jun-16-25 08:00AM	Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA (vonoprazan) Tablets Through May 3, 2032 (GlobeNewswire)
Jun-09-25 09:55AM	Wall Street Analysts Believe Phathom Pharmaceuticals (PHAT) Could Rally 107.4%: Here's is How to Trade (Zacks)
Jun-06-25 12:45PM	Phathom Pharmaceuticals shares soar on FDA exclusivity grant (Investing.com) +90.19%
12:27PM	Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA (vonoprazan) Tablets through May 3, 2032 (GlobeNewswire)
May-15-25 07:59AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +7.08%
May-08-25 09:35AM	After Plunging -45.82% in 4 Weeks, Here's Why the Trend Might Reverse for Phathom Pharmaceuticals (PHAT) (Zacks)
May-02-25 03:02AM	Phathom Pharmaceuticals Inc (PHAT) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com) -17.86%
May-01-25 04:15PM	Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -21.68%
12:09PM	Phathom Pharmaceuticals, Inc. (PHAT) Q1 2025 Earnings Call Transcript (Seeking Alpha)
08:15AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Apr-28-25 07:59AM	Phathom Pharmaceuticals to Present VOQUEZNA (vonoprazan) Data at DDW 2025 Annual Meeting (GlobeNewswire)
Apr-23-25 08:00AM	Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025 (GlobeNewswire)
Apr-16-25 08:00AM	Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors (GlobeNewswire) -11.43%
Apr-08-25 07:09AM	Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains? (Zacks) -12.73%
Apr-03-25 11:25AM	Phathom Pharmaceuticals: The Clock Is Ticking On Voquezna (Downgrade) (Seeking Alpha) -8.83%
08:00AM	Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-01-25 04:15PM	Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -18.34% +7.23%
08:00AM	Phathom Pharmaceuticals Announces Leadership Succession (GlobeNewswire)
Mar-31-25 07:59AM	Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA (vonoprazan) (GlobeNewswire)
Mar-07-25 02:08AM	Phathom Pharmaceuticals Inc (PHAT) Q4 2024 Earnings Call Highlights: FDA Approval Boosts ... (GuruFocus.com) -14.24%
Mar-06-25 09:10AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Mar-05-25 07:21AM	Earnings To Watch: Phathom Pharmaceuticals Inc (PHAT) Reports Q4 2024 Result (GuruFocus.com) +8.96%
Feb-24-25 08:00AM	Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025 (GlobeNewswire) -5.82%
Jan-29-25 08:00AM	Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference (GlobeNewswire)
Dec-12-24 09:39AM	Do You Believe in the Growth Potential of Phathom Pharmaceuticals (PHAT)? (Insider Monkey)
Dec-11-24 08:00AM	Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA (vonoprazan) Tablets (GlobeNewswire) -5.99%
Dec-06-24 09:35AM	Down -54.05% in 4 Weeks, Here's Why Phathom Pharmaceuticals (PHAT) Looks Ripe for a Turnaround (Zacks) +5.88%
Nov-19-24 12:00PM	Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's What You Should Know (Zacks) +5.40%
Nov-08-24 06:02AM	Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com) -8.86%
Nov-07-24 09:20AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-06-24 07:21AM	Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Report Preview: What to Look For (GuruFocus.com)
Nov-04-24 08:00AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-28-24 08:00AM	Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024 (GlobeNewswire) +8.29%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Parikh Asit	Director	May 20 '26	Option Exercise	4.95	17,500	86,625	52,122	May 21 05:16 PM
Parikh Asit	Director	Jan 13 '26	Option Exercise	10.30	8,750	90,125	131,000	Jan 15 04:45 PM
Parikh Asit	Director	Dec 19 '25	Option Exercise	10.30	8,750	90,125	122,250	Dec 23 05:00 PM
Basta Steven L	President and CEO	Nov 28 '25	Option Exercise	0.00	90,000	0	131,625	Dec 02 06:45 PM
Breedlove Robert Charles	Principal Accounting Officer	Nov 03 '25	Sale	13.51	524	7,079	47,407	Nov 05 04:30 PM

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

CEOMr. Steven L. Basta M.B.A.

Co-FounderMr. David A. Socks

M.P.H.Dr. Azmi Nabulsi M.D.

Chief Financial & Business OfficerMr. Sanjeev Narula

J.D.Ms. Anne Marie Cook Esq.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PHAT

Phathom Pharmaceuticals Inc

Upgrade your Finviz experience